Abstract The crucial step in the intrinsic, or mitochondrial, apoptotic pathway is permeabilization of the mitochondrial outer membrane. Permeabilization triggers release of apoptogenic factors, such as cytochrome c, from the mitochondrial intermembrane space into the cytosol where these factors ensure propagation of the apoptotic cascade and execution of cell death. However, the mechanism(s) underlying permeabilization of the outer membrane remain controversial. Two mechanisms, involving opening of two different mitochondrial channels, have been proposed to be responsible for the permeabilization; the permeability transition pore (PTP) in the inner membrane and the mitochondrial apoptosis-induced channel (MAC) in the outer membrane. Opening of PTP would lead to matrix swelling, subsequent rupture of the outer membrane, and an unspecific release of intermembrane proteins into the cytosol. However, many believe PTP opening is a consequence of apoptosis and this channel is thought to principally play a role in necrosis, not apoptosis. Activation of MAC is exquisitely regulated by Bcl-2 family proteins, which are the sentinels of apoptosis. MAC provides specific pores in the outer membrane for the passage of intermembrane proteins, in particular cytochrome c, to the cytosol. The electrophysiological characteristics of MAC are very similar to Bax channels and depletion of Bax 
Controlling the number of cells in multi-cellular organisms is an essential feature from the early embryonic stage, to ensure correct development of organs, and throughout the adult life, to keep a correct balance and provide the body with the cells required at different stages in life. This can be achieved through regulation of cell proliferation, increasing or restricting the creation of new cells, or through the elimination of old and damaged cells or cells that are no longer needed, e.g., activated immune cells. The ultimate regulation is mostly a finely controlled combination of the two processes. The elimination of cells is a tightly regulated process initiated by specific signals, which trigger the targeted cells to commit suicide and die by apoptosis. During this process, DNA fragments into a characteristic degradation pattern and the cell body is dispersed as apoptotic bodies that are eliminated by phagocytosis. Although the end result is the same, there are several means of achieving apoptosis (reviewed in [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] ). The upstream signaling cascades triggering apoptosis are very different depending on the initiating stimuli and the targeted cells to be eliminated. However, as most things in life, this essential process also has a dark side. Apoptosis has also been shown to be associated with a large number of pathological conditions. Left side Upon induction of apoptosis, the multi-domain proapoptotic protein Bax translocates to the outer membrane and both Bax and Bak (yellow) are activated. Bax and/or Bak oligomerize to form MAC, the channel through which proapoptotic factors pass into the cytosol. BH-3 only proteins like t-Bid facilitate and the anti-apoptotic proteins like Bcl-2 block these events. Right side PTP (purple) opens to permeabilize the inner membrane, depolarize the mitochondria, and allow passage of <1500 MW solutes. The matrix space swells, ruptures the outer membrane, and spills pro-apoptogenic factors into the cytosol. Anti-apoptotic proteins, like Bcl-2, block PTP opening. indicates blockade activates the intrinsic pathway to ensure complete execution of apoptosis.
There are two candidate pathways that diverge at the mechanism responsible for the release of mitochondrial mediators of cell death. Both mechanisms result in permeabilization of the outer membrane but do so by activation of two distinct channels. These channels are the permeability transition pore PTP in the inner membrane and the mitochondrial apoptosis-induced channel MAC in the outer membrane ( Fig. 1) .
Opening of the PTP in the inner membrane causes depolarization of the membrane potential and swelling of the matrix space. This swelling ruptures the outer membrane, and spills cytochrome c and other pro-apoptotic proteins into the cytosol [11, 12, [19] [20] [21] . Recent studies of the PTP regulator cyclophilin have raised doubts about the importance of PTP in triggering apoptosis (see below). Furthermore, cytochrome c release can occur in the absence of mitochondrial depolarization and without loss of outer membrane integrity. These observations indicate that, instead of rupturing, a more selective mechanism of permeabilization is operating, like the formation of a pore in the outer membrane [14, [22] [23] [24] [25] [26] .
MAC forms in the mitochondrial outer membrane early in apoptosis and directly provides a pathway for the release of cytochrome c from the intermembrane space to the cytosol. MAC is exquisitely regulated by Bcl-2 family proteins and the multi-domain pro-apoptotic protein Bax and Bak are putative components of this channel [3, 8, 10, 23, 24, 27] . At this time, the complete molecular identity of MAC is not known and studies suggest MAC may contain additional components [28] .
Transient opening of MAC and PTP may alone or in combination, depending on cell type and death stimulus, result in remodeling of the cristae and maximal cytochrome c release to amplify the death signal and ensure completion of apoptosis [10, 29] . Both channels are subject to regulation by Bcl-2 family proteins [23, 24, 30, 31] . The focus of this review is a comparison of MAC and PTP and their possible roles in apoptosis.
Characterization of Bax channels
The three-dimensional structures of the Bcl-2 family proteins show close resemblance to bacteria toxins that form channels [32] [33] [34] . The proteins possess two central hydrophobic helixes surrounded by amphipathic helixes. It is somewhat surprising that this structural arrangement appears to be conserved in both pro-and anti-apoptotic members of the Bcl-2 family. Consistent with this common structure, both the antiand the pro-apoptotic proteins have channel-forming activity in vitro, although the channel forming conditions differ [35] [36] [37] . In normal healthy cells, Bax is present as a cytosolic, monomeric protein, which doesn't have channel-forming capacity [38] . However, once activated, Bax translocates to mitochondria; it is then inserted into the outer membrane and oligomerizes to form large channels [39] .
Activation of Bax is associated with conformational changes in both the C-and the N-terminal parts of the protein [34, 40, 41] . In vitro activation can be induced by either exposing the protein to detergents, like Triton X-100 or octyl glycoside, or through interactions with t-Bid, a natural activator of the multi-domain proteins [38, 39, 42] . Oligomeric Bax forms slightly cation-selective, voltage-independent channels with a variable conductance from a few pS of up to several nS [35, 42] . The diameter estimated for the Bax channels from the peak conductance of 1-5.4 nS is 2.7-5.4 nm, indicating many Bax channels could easily allow the passage of ∼3 nm cytochrome c (see Table 1 ) [23, 43] . Bax channels have been shown to increase the permeability of liposomes to small molecules, like 5,6-carboxyfluorescein and fluorescein-dextran [39, 44] . One study showed that Bax tetramers inserted into liposomes and formed channels large enough to allow the release of cytochrome c, which demonstrated that Bax alone is able of creating channels large enough for the passage of mitochondrial proteins through membranes [44] . Bax channels and the release of various compounds from liposomes are blocked by the anti-apoptotic proteins Bcl-2 and Bcl-xL [35] . Furthermore, cytochrome c and RNAse A induce Type 1 and Type 2 effects in recombinant Bax channels, while hemoglobin has no effect [24] . Type 1 effects are a reversible 5-50% decrease in conductance that is voltage dependent. Type 2 effects are a larger decrease in conductance that is not reversible or voltage dependent.
In contrast to Bax, Bak is always found in the mitochondria. While Bak need not translocate, its activity is presumably induced through oligomerization of Bak molecules already in the membrane [45] . Extensive in vitro studies of Bak have been hampered mainly by difficulties in obtaining sufficient quantities of purified recombinant protein. While intriguing, the role of the mitochondrial fission e Calculated from peak transition size assuming 7 nm pore length [99] and fusion machinery in activation and/or oligomerization of Bax and/or Bak as well as cytochrome c release are yet to be determined [46] . In order to study Bax channel activity and its relevance to apoptosis, specific Bax channel blockers were developed. The action of these blockers was tested in both in vitro and in vivo apoptosis model systems [47] (see Fig. 4 and discussion below). recorded in both planar bilayers and liposomes. As described below, studies have demonstrated that Bax is a component of MAC in apoptotic HeLa and MEF cell lines. In contrast, the activity of MAC is significantly different from the constitutive channels of the mitochondrial outer membrane, TOM and VDAC. The single channel parameters of peak conductance, transition size, selectivity, and voltage dependence for these channels are shown in Table 1 and illustrated by the current traces of Fig. 2 .
Electrophysiological characterization of MAC
Efforts to characterize MAC have focused on the activity detected at the time of cytochrome c release. Like Bax, this channel is slightly cation-selective, which is consistent with MAC's putative role in releasing the cationic protein cytochrome c. MAC is typically a voltage-independent channel [23-25, 27], although it has also been reported to occupy less than peak conductance at higher potentials [29] . Conductance is a measure of channel size and the conductance of MAC at the time of cytochrome c release is both variable and high [23, 24] . The mean conductance of MAC of apoptotic HeLa and FL5.12 cells is 3.3 and 4.5 nS, respectively [23] [24] [25] . The polymer exclusion method shows 4 nS MAC channels are permeable to 10 and 17 kDa, but not 45 and 71 kDa Dextran [24] . This approach indicates that channels with a conductance between 1.5 and 5 nS have pore sizes in the range of 3.3-6.0 nm.
The release of cytochrome c, which has a diameter of ∼3 nm [43] , occurs earlier than that of other pro-apoptotic factors in some systems [48] [49] [50] . However, there are reports of cytochrome c release at the same time as several higher MW pro-apoptotic factors including SMAC/Diablo and AIF [49] [50] [51] [52] [53] . Importantly, MAC has only been characterized early in apoptosis at the time of cytochrome c release. It is likely that the mean pore size of MAC increases as apoptosis progresses possibly by incorporation of additional Bax and/or Bak molecules into the MAC channel complex, or perhaps by other, as yet unidentified, components.
Cytochrome c and RNAase A cause a reversible voltagedependent decrease in MAC conductance, ( Table 2 , Type 1 effect) consistent with their partitioning into the pore [24] . These molecules have the same effects on pure Bax channels [23] . While hemoglobin has no effect, cytochrome c and RNAase can also cause a Type 2 effect, which is an irreversible, voltage-independent closure of MAC. Importantly, and similar to Bax channel activity, over-expression of Bcl-2 blocks formation of MAC and release of cytochrome c [25].
Bax and Bak are functionally redundant with respect to MAC
MAC and Bax channel activities appear to be identical when examined with electrophysiological techniques; they are very large conductance channels that are essentially voltage independent, have many substates, and a variable peak conductance. These functional similarities suggest Bax and MAC constitute the same entity. Furthermore, the initial time of MAC detection coincides with the time of translocation of Bax to the mitochondrial membrane. Hence, the possibility that Bax is a component of MAC was examined with biochemical and molecular approaches.
Immunoprecipitation of oligomeric Bax results in a depletion of MAC activity from lysates of staurosporine-treated HeLa cells. Bax oligomerizes in the outer membrane following its translocation to mitochondria, which is coincident with cytochrome c release [22, 23, 28, 54] . MAC activity is present in total mitochondrial lysates and the activity co-elutes with chromatography fractions containing oligomeric Bax, but not monomeric Bax (Fig. 3) [23]. Importantly, Bax antibodies raised against an N-terminal epitope of the protein deplete MAC activity from solubilized mitochondrial fractions [23] . The N-terminal epitope is not accessible in monomeric Bax but is exposed following activation of Bax. Therefore, these antibodies selectively precipitate oligomeric, not monomeric, Bax [40, 41] . The concomitant loss of MAC activity upon immunoprecipitation of oligomeric Bax indicates that Bax is a component of MAC in this system.
The relationship between MAC and the multi-domain proapoptotic proteins Bax and Bak was further examined using molecular approaches. Previous studies using single and double knock out cell lines for Bax and Bak showed these two proteins are functionally redundant with respect to their roles in apoptosis (see [1, 2, 5 , 9] for review). That is, cytochrome c release occurs in Bax and Bak single knockout cells but not in the double Bax/Bak knockout cells during staurosporine treatment (Fig. 3) [23, 26] . Similarly, MAC is detected in single knockout, but not the double knockout cell lines during apoptosis (Fig. 3) . As immunodepletion studies showed Bax is a component of MAC in apoptotic HeLa cells, these data indicate that Bak can replace Bax as a structural component of MAC in Bax deficient cells. That is, Bax and Bak are functionally redundant with respect to MAC.
Because of these findings, recombinant Bax has become a valuable model system for studying both MAC and cytochrome c release. Unfortunately, difficulties in producing recombinant forms of other multi-domain pro-apoptotic proteins like Bak have excluded their electrophysiological characterization and usefulness as model systems.
Electrophysiological characterization of PTP
While MAC directly permeabilizes the mitochondrial outer membrane to release cytochrome c, the permeability transition pore PTP indirectly releases apoptogenic factors from the intermembrane space. Opening of PTP causes depolarization and swelling of the matrix space. Since the inner membrane has a surface area several times that of the outer membrane, swelling of the matrix space results in rupture of the outer membrane and a spilling of intermembrane space proteins into the cytosol.
The PTP was originally described in swelling experiments (detected as changes in scatter) on isolated mitochondria in landmark studies more than 25 years ago (Fig. 4) [55] [56] [57] [58] . Opening of the PTP leads to an increase in permeability of the mitochondrial inner membrane for solutes up to 1.5 kDa and is typically studied by changes in light scattering, i.e., absorbance. PTP can often be reversibly closed by removal of calcium with EGTA or by the addition of cyclosporine A, magnesium or ADP. The PTP can be activated by a myriad of effectors including calcium plus phosphate and reactive oxygen species. This channel has been implicated in the apoptotic cascade as a means of releasing cytochrome c from mitochondria [11, 12, 19, 29] .
The connection between the PTP and channel activities recorded directly from the inner membrane (by patch clamping mitoplasts) was made over a few years by several investigators and culminated in a series of papers from Mario Zoratti's group [59] [60] [61] [62] [63] [64] [65] . In earlier studies, PTP channel activity was referred to as MCC (mitochondrial multiple conductance channel) or MMC (mitochondrial megachannel). Although much smaller than MAC and Bax channels, PTP is a high conductance channel ( Table 1 ). The peak conductance is ∼1.2 nS and there are multiple conductance levels. Transitions between sublevels are typically 0.3-1 nS. Unlike MAC and Bax channels, this slightly cation selective channel is voltage dependent, closing with matrix positive potentials. Interestingly, while overexpression of Bcl-2 had no detectable effect on the channel activity, this protein suppressed calcium-activation of the PTP in both swelling and electrophysiological experiments [30, 31] .
While MAC contains at least Bax and/or Bak, the molecular identity of PTP has not yet been resolved. The adenine nucleotide translocator or ANT was for many years thought to be tightly linked to the PTP because of the ability of Bongkrekic acid to close PTP and inhibit ANT while atractyloside opens PTP and ANT. Hence, it was quite surprising that the PTP remained after the genes responsible for the ANT were knocked out by Wallace's group [66] . They reported that ANT confers effector sensitivity to the PTP, but ANT does not provide the pore for the PTP. However, a more recent report indicates that there is yet a fourth isoform of ANT in liver, testis and brain [67] that is sensitive to both to carboxyatractyloside and bongkrekic acid. While these findings have returned some of the spotlight to ANT's putative role in PTP, the controversy continues. The voltage dependent anion-selective channel or VDAC (also called mitochondrial porin) is another putative component of the PTP in the outer membrane. Molecular studies of VDAC null mice are not possible as this channel is essential for viability. Efforts to generate a knockout of all three isoforms of VDAC in mammalian cells have not been successful and so the role of VDAC in PTP remains unknown [68] . However, studies suggest VDAC might have roles in apoptosis as a target of anti-apoptotic proteins and in sequestration of Bak [69] [70] [71] [72] . Nevertheless, the lack of a molecular identity for PTP has significantly hampered progress in our understanding of this phenomenon and its putative role in apoptosis.
Does PTP have a role in apoptosis?
At this time, the role of the PTP in apoptosis is quite controversial. While some studies implicate PTP as an initiating event in the mitochondrial pathway [11, 12, [73] [74] [75] , others indicate PTP opening is a consequence of the degradation stage of apoptosis. Compounds that induce the permeability transition in isolated mitochondria often cause apoptosis and PTP is blocked or delayed by the anti-apoptotic drug cyclosporine A [64, [76] [77] [78] . Suppression of the calciumactivation of the PTP by overexpression of Bcl-2 supports a role for this channel in apoptosis [31, 79] . While some believe PTP plays a major role in the mitochondrial pathway of apoptosis, recent studies show that sustained PTP opening is instead predominantly involved in necrosis and ischemia-reperfusion injury [80] [81] [82] .
Cyclophilin-D is a regulator of the PTP. Surprisingly, cells deficient in cyclophilin-D die normally after activation of either the extrinsic or intrinsic pathways, but show resistance to necrotic cell death induced by reactive oxygen species and Ca 2+ overload [80] [81] [82] . These findings strongly indicate that PTP opening is a consequence, rather than an initiator, of apoptosis [83] [84] [85] . Nevertheless, the opening of PTP, although subsequent to MAC, may result in a more complete release of cytochrome c and other pro-apoptotic factors from the cristae, which would synergistically amplify the apoptotic cascade initiated by MAC. Furthermore, the delay in the progression of apoptosis caused by PTP inhibitors like cyclosporine A may be related to their ability to delay depolarization and energy production as well as any synergistic effects of further cytochrome c release from the cristae.
Pharmacology of MAC, Bax, and PTP
The ability to open or close MAC and PTP inside cells can have far reaching therapeutic value and may offer clues as to the underlying mechanisms of apoptosis. MAC and PTP are potential targets for novel therapies since opening MAC and PTP with agonists may induce cell death while preventing their opening with blockers may prevent cell death. Some of the blockers and inducers of PTP and MAC activity are shown in Table 2 . Comprehensive lists of PTP effectors have been presented in reviews [78, 86] . Cyclosporine A has long been used to delay apoptotic death and is a PTP blocker with nM affinity [11, 76, 77] . However, cyclosporine A does not block MAC channels [27] . While trifluoperazine, dibucaine, and propranolol block both MAC and PTP, there appear to be significant differences in IC 50 for the two channels [27, 87, 88] . More recently, a promising study identified two blockers of Bax channels, i.e., MAC [47] (Fig. 5) . These blockers, bci1 and bci2, prevented cytochrome c release in vitro and in vivo and protected neurons in a mice animal model of brain ischemia [47] . This and other studies indicate that MAC and perhaps PTP are potential therapeutic targets to reduce tissue damage associated with ischemic events, i.e. infarction and stroke. Unfortunately, many agents affecting PTP were identified prior to characterization of MAC. Hence, their ability to prevent cytochrome c release may need to be reevaluated in light of the integral role of MAC in this process. Future studies could perhaps rely on the findings that the mitochondrial swelling and depolarization associated with PTP opening are not thought to be associated with MAC formation.
Cytochrome c and RNAase A have been shown to reversibly and transiently reduce the conductance through MAC. However, the effects of these proteins demonstrate that they partition into the pore and are translocated as has been found with DNA or ATP moving into Hemolysin A channels or VDAC, respectively [89, 90] . These effects are distinct from those found with compounds like dibucaine 
MAC or PTP?
How can one determine whether mitochondrial apoptosis is due to the opening of MAC or PTP? Activation of both pores release cytochrome c. The two pores differ in their effects on the mitochondrial membrane potential and the ability to make ATP. Opening PTP depolarizes mitochondria and uncouples oxidative phosphorylation, while MAC, at least initially, does not. MAC was discovered by patch clamping mitochondria of FL5. 12 cells twelve hours after interleukin-3 withdrawal. At this time, the mitochondria still maintain their membrane potential as indicated by Rhodamine 123 staining. However, the mitochondria are depolarized by eighteen hours (unpublished data of Kinnally). These data indicate that MAC formation occurred in the absence of PTP opening in these cells after IL-3 withdrawal. There have been several reports that release of cytochrome c occurs prior to depolarization [14] . Hence, these events are not necessarily synchronized. Cytochrome c release corresponds to MAC formation when release is not accompanied by mitochondrial depolarization. However, the mechanism of release is less clear if the onset of cytochrome c release cannot be resolved from depolarization, as depletion of cytochrome c from the electron transport network OR opening of PTP may underlie mitochondrial depolarization [91] . Alternatively, the two channels can be distinguished pharmacologically by the ability of cyclosporine A to block PTP and bci1 to block MAC [47, 76] .
Apoptosis in disease
Although apoptosis is an essential process for all multicellular organisms, it is also involved or associated with a wide range of diseases and pathological conditions [92] [93] [94] [95] [96] [97] . This has made apoptosis an attractive potential target for treatment of various diseases. Deregulation of the apoptosis processes can lead to either an inappropriate increase in apoptosis, associated with diseases such as ischemia and neurodegenerative pathologies, or to impaired apoptosis, frequently associated with various cancers and autoimmune diseases. Thus, regulation of apoptosis in these pathologies could be beneficial. However, several issues need to be addressed before a successful regulation of apoptosis can be implemented for treatment of diseases.
As mentioned above, apoptosis is an essential physiological process and a too broad disturbance of this process will inevitably result in severe side effects. Early on, the executioner caspases were envisioned as crucial anti-apoptotic targets, since several apoptosis signaling cascades converge at this point. Hence, it was thought that it would not be necessary to know which apoptosis signaling cascade was involved in the disease process. Such attempts failed, due to toxicity and severe side effects, presumably due to inhibition of essential apoptotic processes. A main problem in treating diseases is that the apoptosis pathway involved in a specific pathology is often not known. In order to be successful and minimize undesired side effects and toxicity, the intervention needs to be targeted as specifically as possible in order to inhibit or activate just the pathway involved in the disease process. In general, this means that we should intervene as upstream in the pathway as possible. For example, if we want to prevent apoptosis mediated through the mitochondrial pathway, the best point of intervention would presumably be at the activation step of Bax and/or Bak, before the proteins get activated and perturb mitochondrial function through their oligomerization in the membrane. This would restrict perturbation of apoptosis signaling in the cells, affecting only the specific activation signal, and leave other Bax/Bak activating processes functional. It would also retain fully functional mitochondria in the cells, which might be extremely important.
In most pathological conditions, apoptosis is not the direct cause of the disease. Hence, it is difficult to predict the effect that inhibition of apoptosis will have in the disease process. Inhibition of apoptosis could limit or prevent damage and tissue destruction, which should favor recovery and reduce impairments. In several diseases cell death is not exclusively by apoptosis. Necrosis is often also involved and the border between the two processes is not very well defined. One could also envision that cells may enter the apoptosis cascade but then ultimately die by necrosis because of changing conditions [98] . Thus, any apoptosis treatment must also ensure that cells are not just switched to a pathway of necrotic death, which may, in the end, aggravate instead of ameliorate the condition. It is also obvious that activation of programmed cell death must be focused to the target cells in diseases with impaired apoptosis in order to minimize side effects by not inducing inappropriate apoptosis in other cells and tissues.
Conclusions
Mitochondria provide the gateway through which apoptosis can be executed in a rapid and robust manner. There are two pathways by which cytochrome c can be released from mitochondria to commit the cell to die; activation of either MAC in the outer membrane or PTP in the inner membrane can effectuate this event. At the present time, the evidence indicates that MAC, which is exquisitely regulated by Bcl-2 family proteins, is a principal means of commitment to apoptosis. Activation of the PTP may in fact be a consequence of apoptosis, but its activation may ensure complete execution of the cell. Nevertheless, both PTP and MAC remain potential therapeutic targets which should be exploited to induce cell death in malignancies and prevent cell death in degenerative and ischemia-associated pathologies. 
